YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Functional Constipation

Conditions

Functional Constipation

Trial Timeline

Aug 1, 2015 → Sep 1, 2016

About YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo

YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo is a phase 1/2 stage product being developed by Yuhan for Functional Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT02538367. Target conditions include Functional Constipation.

What happened to similar drugs?

0 of 6 similar drugs in Functional Constipation were approved

Approved (0) Terminated (1) Active (5)
🔄Imonogas + EspumisanJohnson & JohnsonPhase 3
🔄Linaclotide + PlaceboAbbViePhase 3
Gabapentin + PlaceboPfizerPhase 3
🔄Z-338 + PlaceboZeria PharmaceuticalPhase 3
🔄Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02538367Phase 1/2Completed

Competing Products

20 competing products in Functional Constipation

See all competitors
ProductCompanyStageHype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + PlaceboYuhanPhase 2
27
YM443 + Placebo + MoxifloxacinAstellas PharmaPhase 1
29
Rabeprazole + Rabeprazole + Rabeprazole + PlaceboEisaiPhase 2
35
Imonogas + EspumisanJohnson & JohnsonPhase 3
40
Linaclotide + PlaceboAbbViePhase 3
40
Linaclotide + Placebo for LinaclotideAbbViePhase 3
40
Linaclotide + PlaceboAbbViePhase 2
35
Quetiapine (50 mg/day-100mg/day)AstraZenecaPre-clinical
26
NKTR-118AstraZenecaPhase 1
29
PDR001NovartisPhase 2
35
Human GLP-1 (7-36) amide + Isotone NaClNovo NordiskPre-clinical
26
psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo)PfizerPre-clinical
26
Gabapentin + PlaceboPfizerPhase 3
32
Z-338Zeria PharmaceuticalPhase 2
35
Z-338 + PlaceboZeria PharmaceuticalPhase 3
40
Acotiamide hydrochloride hydrate + PlaceboZeria PharmaceuticalPhase 3
44
Z-338Zeria PharmaceuticalPhase 2
35
MibavademabRegeneron PharmaceuticalsPhase 2
42
STW5 (Iberogast®, BAY98-7411) + PlaceboBayerPhase 2
32
Iberogast (STW5-II, BAY98-7410)BayerPre-clinical
23